This study will evaluate progression-free survival (PFS)for the regimen of gemcitabine and bevacizumab with or without a platinum agent on platinum-resistant/refractory ovarian and peritoneal carcinoma

Disease progression during or within 6 months of previous platinum-based chemotherapy including the following 4 categories:

Primary platinum-refractory: Previously untreated patients who do not achieve at least a partial response to platinum-based chemotherapy

Primary platinum-resistant: Previously untreated patients who have achieved at least a partial response to platinum-based chemotherapy but experience a relapse within a period of 6 months of its conclusion

Secondary platinum-refractory: Previously treated patients have a relapse 6 months after the conclusion of chemotherapy, but fail to achieve at least a partial response

Secondary platinum-resistant: Previously treated patients have a relapse 6 months after the conclusion of chemotherapy, achieve at least a partial response with platinum-based therapy as 2nd-line therapy, but experience relapse within 6 months

Prior treatment with more than three (3) lines of chemotherapy including adjuvant chemotherapy

Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug

Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements

Concurrent severe illness such as active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01936974